Drug Discovery for Parasitic Diseases

寄生虫病药物发现

基本信息

批准号：
9045149
负责人：
DAVID L. WOODLAND
金额：
$ 0.5万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-01-06 至 2016-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9045149
关键词：
Academia Advanced Development African Trypanosomiasis Antiparasitic Agents Biology California Cells Cessation of life Chagas Disease Chemicals Cities Clinical Trials Collaborations Communication Drug Combinations Drug Kinetics Drug Targeting Drug resistance Drug toxicity Emerging Technologies Fostering Fruit Genomics Goals Helminths Human Industry Infection Knowledge Lead Leishmaniasis Malaria Methodology Methods Nature Organism Outcome Parasites Parasitic Diseases Parasitic infection Parasitology Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacotherapy Phase Play Process Protozoa Regimen Research Research Personnel Role Safety Schistosomiasis Science Scientist Staging Technology Therapy Evaluation Validation Work base biological systems candidate selection cheminformatics chemoproteomics clinical practice drug development drug discovery drug metabolism high throughput screening human disease improved interest meetings metabolomics novel novel therapeutics pathogen posters programs public health relevance resistance mechanism screening small molecule libraries student training symposium transcriptomics

Academia Advanced Development African Trypanosomiasis Antiparasitic Agents Biology California Cells Cessation of life Chagas Disease Chemicals Cities Clinical Trials Collaborations Communication Drug Combinations Drug Kinetics Drug Targeting Drug resistance Drug toxicity Emerging Technologies Fostering Fruit Genomics Goals Helminths Human Industry Infection Knowledge Lead Leishmaniasis Malaria Methodology Methods Nature Organism Outcome Parasites Parasitic Diseases Parasitic infection Parasitology Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacotherapy Phase Play Process Protozoa Regimen Research Research Personnel Role Safety Schistosomiasis Science Scientist Staging Technology Therapy Evaluation Validation Work base biological systems candidate selection cheminformatics chemoproteomics clinical practice drug development drug discovery drug metabolism high throughput screening human disease improved interest meetings metabolomics novel novel therapeutics pathogen posters programs public health relevance resistance mechanism screening small molecule libraries student training symposium transcriptomics

展开

项目摘要

DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Drug Discovery for Parasitic Diseases, organized by Leann M. Tilley, Philip J. Rosenthal and Kelly Chibale. The meeting will be held in Tahoe City, California from January 24-28, 2016. Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches - target-based methods that build on improved understanding of parasite biology; phenotypic high throughput screens, that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics, and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.

描述（由申请人提供）：请求支持Keystone研讨会会议，标题为“寄生疾病的药物发现”，由Leann M. Tilley，Philip J. Rosenthal和Kelly Chibale组织。会议将于2016年1月24日至28日在加利福尼亚州塔霍市举行。寄生生物，包括原生动物和蠕虫，是最重要的人类病原体之一，每年引起数十亿次感染和数百万人死亡。对于许多寄生疾病，可用的疗法是不令人满意的，并且越来越受到耐药性的威胁。迫切需要针对新目标的新疗法，理想地针对新的靶标。抗寄生液药物发现的最新进展来自三种不同的方法 - 基于目标的方法，这些方法基于对寄生虫生物学的理解的改善；表型高吞吐量屏幕，这些屏幕从改进的技术中受益；并重新定位和重新利用用于其他适应症的药物。这些不同的方法都受益于将医学化学与寄生和药物治疗计划的整合。这次会议将展示尖端的反寄生毒发现计划，以说明从寄生虫生物学到铅鉴定以及从优化到候选人选择的路径。它将强调需要在医学化学，寄生虫生物学，药代动力学和安全评估中协调计划的整合。它将采用新兴技术，例如化学生物学，化学蛋白质组学，化学信息学，基因组学，转录组学和代谢组学，支持药物发现。它还将讨论抗寄生毒抗药性的当前状态以及我们对抗药性机制的理解。这次会议应该引起医学化学家，寄生虫学家，药物发现和发育专家，药物和临床医生的针对原生动物和蠕虫，引起严重的人类疾病，包括疟疾，非洲和美洲锥虫病，利什曼病，利什曼病，schistosomiasis，Schistosomiasis以及多种其他寄生虫感染。